Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 382

1.

Pharmacokinetic/Pharmacodynamic Relationship of Enzalutamide and Its Active Metabolite N-Desmethyl Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Patients.

Joulia ML, Carton E, Jouinot A, Allard M, Huillard O, Khoudour N, Peyromaure M, Zerbib M, Schoemann AT, Vidal M, Goldwasser F, Alexandre J, Blanchet B.

Clin Genitourin Cancer. 2019 Jun 13. pii: S1558-7673(19)30158-2. doi: 10.1016/j.clgc.2019.05.020. [Epub ahead of print]

PMID:
31630979
2.

PLEKHS1: A new molecular marker predicting risk of progression of non-muscle-invasive bladder cancer.

Pignot G, Le Goux C, Vacher S, Schnitzler A, Radvanyi F, Allory Y, Lallemand F, Delongchamps NB, Zerbib M, Terris B, Damotte D, Bieche I.

Oncol Lett. 2019 Oct;18(4):3471-3480. doi: 10.3892/ol.2019.10706. Epub 2019 Aug 2.

3.

[Multidisciplinary and systematic preoperatory-assessment in geriatric urologic oncology surgery: Feasibility and results].

Prin-Touvron L, Huillard O, Xylinas E, Orvoen G, Boudou-Rouquette P, Barry Delongchamps N, Zerbib M, Peyromaure M, Alexandre J, Goldwasser F.

Prog Urol. 2019 May - Jun;29(6):318-325. doi: 10.1016/j.purol.2019.04.008. Epub 2019 May 29. French.

PMID:
31153857
4.

Study of the intra-prostatic arterial anatomy and implications for arterial embolization of benign prostatic hyperplasia.

Anract J, Amouyal G, Peyromaure M, Zerbib M, Sapoval M, Barry Delongchamps N.

Prog Urol. 2019 Apr;29(5):263-269. doi: 10.1016/j.purol.2019.02.007. Epub 2019 Apr 1.

PMID:
30948187
5.

[Interest of a systematic assessment of the treatment of the lower urinary tract symptoms in the management of benign prostatic hypertrophy in general practice (1380 patients) - Study EVALURO].

Descazeaud A, Coloby P, De La Taille A, Kouri G, Mallet R, Rossi D, Rozet F, Zerbib M, Carrois F.

Prog Urol. 2019 Feb;29(2):116-126. doi: 10.1016/j.purol.2018.12.003. Epub 2019 Jan 18. French.

PMID:
30665818
6.

[Urinary incontinence after HOLEP: Incidence, evolution and predictive factors].

Sapetti J, Sakat J, Saad E, Zerbib M, Belas O, Doru-Pop C, Peyromaure M, Delongchamps NB.

Prog Urol. 2019 Feb;29(2):101-107. doi: 10.1016/j.purol.2018.12.008. Epub 2019 Jan 17. French.

PMID:
30661941
7.

Criteria for indication and treatment modification in a cohort of patients with prostate cancer treated with hormone therapy.

Lebret T, Ruffion A, Latorzeff I, Zerbib M, Moreau JL, Rossi D, Pello-Leprince-Ringuet N, Perrot V, Hennequin C.

Ther Adv Urol. 2018 Oct 24;10(12):365-376. doi: 10.1177/1756287218808496. eCollection 2018 Dec.

8.

Deterministic Somatic Cell Reprogramming Involves Continuous Transcriptional Changes Governed by Myc and Epigenetic-Driven Modules.

Zviran A, Mor N, Rais Y, Gingold H, Peles S, Chomsky E, Viukov S, Buenrostro JD, Scognamiglio R, Weinberger L, Manor YS, Krupalnik V, Zerbib M, Hezroni H, Jaitin DA, Larastiaso D, Gilad S, Benjamin S, Gafni O, Mousa A, Ayyash M, Sheban D, Bayerl J, Aguilera-Castrejon A, Massarwa R, Maza I, Hanna S, Stelzer Y, Ulitsky I, Greenleaf WJ, Tanay A, Trumpp A, Amit I, Pilpel Y, Novershtern N, Hanna JH.

Cell Stem Cell. 2019 Feb 7;24(2):328-341.e9. doi: 10.1016/j.stem.2018.11.014. Epub 2018 Dec 13.

PMID:
30554962
9.

Evolution of Flavanol Glycosides during Red Grape Fermentation.

Zerbib M, Cazals G, Ducasse MA, Enjalbal C, Saucier C.

Molecules. 2018 Dec 12;23(12). pii: E3300. doi: 10.3390/molecules23123300.

10.

High Prevalence of a Hotspot of Noncoding Somatic Mutations in Intron 6 of GPR126 in Bladder Cancer.

Garinet S, Pignot G, Vacher S, Le Goux C, Schnitzler A, Chemlali W, Sirab N, Barry Delongchamps N, Zerbib M, Sibony M, Allory Y, Damotte D, Bieche I.

Mol Cancer Res. 2019 Feb;17(2):469-475. doi: 10.1158/1541-7786.MCR-18-0363. Epub 2018 Nov 6.

PMID:
30401719
11.

New flavanol O-glycosides in grape and wine.

Zerbib M, Mazauric JP, Meudec E, Le Guernevé C, Lepak A, Nidetzky B, Cheynier V, Terrier N, Saucier C.

Food Chem. 2018 Nov 15;266:441-448. doi: 10.1016/j.foodchem.2018.06.019. Epub 2018 Jun 5.

PMID:
30381210
12.

Identification and Quantification of Flavanol Glycosides in Vitis vinifera Grape Seeds and Skins during Ripening.

Zerbib M, Cazals G, Enjalbal C, Saucier C.

Molecules. 2018 Oct 24;23(11). pii: E2745. doi: 10.3390/molecules23112745.

13.

Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer and Its Impact on Surgical Morbidity and Oncological Outcomes: A Real-World Experience.

Nguyen TT, Huillard O, Dabi Y, Anract J, Sibony M, Zerbib M, Xylinas E.

Front Surg. 2018 Sep 19;5:58. doi: 10.3389/fsurg.2018.00058. eCollection 2018.

14.

Measurement of white wines resistance against oxidation by Electron Paramagnetic Resonance spectroscopy.

Nikolantonaki M, Coelho C, Noret L, Zerbib M, Vileno B, Champion D, Gougeon RD.

Food Chem. 2019 Jan 1;270:156-161. doi: 10.1016/j.foodchem.2018.07.052. Epub 2018 Jul 11.

PMID:
30174029
15.

Neutralizing Gatad2a-Chd4-Mbd3/NuRD Complex Facilitates Deterministic Induction of Naive Pluripotency.

Mor N, Rais Y, Sheban D, Peles S, Aguilera-Castrejon A, Zviran A, Elinger D, Viukov S, Geula S, Krupalnik V, Zerbib M, Chomsky E, Lasman L, Shani T, Bayerl J, Gafni O, Hanna S, Buenrostro JD, Hagai T, Masika H, Vainorius G, Bergman Y, Greenleaf WJ, Esteban MA, Elling U, Levin Y, Massarwa R, Merbl Y, Novershtern N, Hanna JH.

Cell Stem Cell. 2018 Sep 6;23(3):412-425.e10. doi: 10.1016/j.stem.2018.07.004. Epub 2018 Aug 16.

16.

The visual prostate symptom score is a simple tool to identify and follow up in general practice patients with lower urinary tract symptoms associated with benign prostatic hyperplasia (a study with 1359 patients).

Descazeaud A, Coloby P, Taille A, Karsenty G, Kouri G, Rossi D, Carrois F, Zerbib M.

Presse Med. 2018 Jul - Aug;47(7-8 Pt 1):e91-e98. doi: 10.1016/j.lpm.2018.06.011. Epub 2018 Jul 31.

PMID:
30075950
17.

mRNA Expression levels of genes involved in antitumor immunity: Identification of a 3-gene signature associated with prognosis of muscle-invasive bladder cancer.

Le Goux C, Vacher S, Pignot G, Sibony M, Barry Delongchamps N, Terris B, Piaggio E, Zerbib M, Damotte D, Bieche I.

Oncoimmunology. 2017 Aug 14;6(11):e1358330. doi: 10.1080/2162402X.2017.1358330. eCollection 2017.

18.

Impact of body mass index on the oncological outcomes of patients treated with radical nephroureterectomy for upper tract urothelial carcinoma.

Dabi Y, El Mrini M, Duquesnes I, Delongchamps NB, Sibony M, Zerbib M, Xylinas E.

World J Urol. 2018 Jan;36(1):65-71. doi: 10.1007/s00345-017-2095-4. Epub 2017 Oct 14.

PMID:
29032451
19.

The HIV-1 viral synapse signals human foreskin keratinocytes to secrete thymic stromal lymphopoietin facilitating HIV-1 foreskin entry.

Zhou Z, Xu L, Sennepin A, Federici C, Ganor Y, Tudor D, Damotte D, Barry Delongchamps N, Zerbib M, Bomsel M.

Mucosal Immunol. 2018 Jan;11(1):158-171. doi: 10.1038/mi.2017.23. Epub 2017 Apr 26.

PMID:
28443609
20.

Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.

Le Goux C, Damotte D, Vacher S, Sibony M, Delongchamps NB, Schnitzler A, Terris B, Zerbib M, Bieche I, Pignot G.

Urol Oncol. 2017 May;35(5):257-263. doi: 10.1016/j.urolonc.2017.01.014. Epub 2017 Mar 11.

PMID:
28291636
21.

[Validation of visual prostate symptom score, VPSS, in the evaluation of lower urinary tract symptoms associated with benign prostatic hyperplasia (550 patients)].

Descazeaud A, Coloby P, Davin JL, De La Taille A, Karsenty G, Kouri G, Rossi D, Pouteau JC, Zerbib M.

Prog Urol. 2017 Mar;27(3):176-183. doi: 10.1016/j.purol.2017.01.002. Epub 2017 Mar 9. French.

PMID:
28285780
22.

Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients.

Carton E, Noe G, Huillard O, Golmard L, Giroux J, Cessot A, Saidu NE, Peyromaure M, Zerbib M, Narjoz C, Guibourdenche J, Thomas A, Vidal M, Goldwasser F, Blanchet B, Alexandre J.

Eur J Cancer. 2017 Feb;72:54-61. doi: 10.1016/j.ejca.2016.11.027. Epub 2016 Dec 24.

PMID:
28027516
23.

Impact of body mass index on the oncological outcomes of patients treated with radical cystectomy for muscle-invasive bladder cancer.

Dabi Y, Rouscoff Y, Anract J, Delongchamps NB, Sibony M, Saighi D, Zerbib M, Peyraumore M, Xylinas E.

World J Urol. 2017 Feb;35(2):229-235. doi: 10.1007/s00345-016-1852-0. Epub 2016 Jun 6.

PMID:
27272203
24.

[Negative prognostic impact of female gender on oncological outcomes following radical cystectomy].

Dabi Y, Rouscoff Y, Delongchamps NB, Sibony M, Saighi D, Zerbib M, Peyraumore M, Xylinas E.

Prog Urol. 2016 Feb;26(2):83-8. doi: 10.1016/j.purol.2015.12.001. Epub 2016 Jan 12. French.

PMID:
26796347
25.

L'IRM de diffusion quantitative améliore la fiabilité du score PIRADS pour le diagnostic du cancer de la prostate.

Cornud F, Barry Delongchamps N, Beuvon F, Camparo P, Zerbib M.

Prog Urol. 2015 Nov;25(13):828-9. doi: 10.1016/j.purol.2015.08.223. French. No abstract available.

PMID:
26544416
26.

L'urétéroscopie diagnostique augmente le risque de récidive vésicale après néphro-urétérectomie totale.

Beurrier S, Lanz C, Elalouf V, Barry Delongchamps N, Sibony M, Saighi D, Zerbib M, Peyromaure M, Xylinas E.

Prog Urol. 2015 Nov;25(13):804-5. doi: 10.1016/j.purol.2015.08.176. French. No abstract available.

PMID:
26544371
27.

Étude prospective multicentrique comparant les voies ouverte et mini-invasive de la prostatectomie totale (Propenlap : résultats fonctionnels).

Salomon L, Bastuji-Garin S, Soulie M, Devonec M, Boutin E, Mandron E, Benoit G, Rischmann P, Mottet N, Gasman D, Irani J, De la Taille A, Zerbib M, Vaesen C, Dore B, Lebret T, Colombel M, Lechevallier E, Gregoire L, Allory Y, Abbou C.

Prog Urol. 2015 Nov;25(13):793. doi: 10.1016/j.purol.2015.08.154. French. No abstract available.

PMID:
26544349
28.

Prostatectomie totale par voies ouvertes et mini-invasives (étude comparative prospective Propenlap) : résultats carcinologiques.

Salomon L, Bastuji-Garin S, Mazerolles C, Devonec M, Soulie M, Benoit G, Rischmann P, Decaussin-Petrucci M, Mottet N, Gasman D, Fromont-Hankard G, Irani J, De la Taille A, Zerbib M, Ferlicot S, Comperat E, Vaesen C, Beuvon F, Lebret T, Boutin E, Mege-Lechevallier F, Dore B, Radulescu C, Paoletti M, Shar A, Colombel M, Lechevallier E.

Prog Urol. 2015 Nov;25(13):792-3. doi: 10.1016/j.purol.2015.08.153. French. No abstract available.

PMID:
26544348
29.

Implication de la voie PD1/PDL1 et de la voie CTLA4/CD80 dans les tumeurs urothéliales.

Pignot G, Le Goux C, Bieche I, Vacher S, Barry de Longchamps N, Sibony M, Zerbib M.

Prog Urol. 2015 Nov;25(13):762. doi: 10.1016/j.purol.2015.08.096. French. No abstract available.

PMID:
26544291
30.

Évaluation des sous-stadifications T1a/b et T1m/e dans la prédiction du devenir oncologique des patients présentant une tumeur de vessie n'infiltrant pas le muscle.

Lanz C, Bucau M, Beurrier S, Barry Delongchamps N, Saighi D, Zerbib M, Peyromaure M, Sibony M, Xylinas E.

Prog Urol. 2015 Nov;25(13):760. doi: 10.1016/j.purol.2015.08.091. French. No abstract available.

PMID:
26544286
31.

Résultats économiques de Propenlap, étude prospective multicentrique comparant les voies ouvertes et mini-invasives de la prostatectomie totale.

Durand-Zaleski I, Rabetrano H, Devonec M, Mandron E, Soulie M, De la Taille A, Benoit G, Mottet N, Gasman D, Dore B, Zerbib M, Vaessen C, Irani J, Lebret T, Colombel M, Lechevallier E, Bastuji-Garin S, Allory Y, Abbou C, Rischmann P, Salomon L.

Prog Urol. 2015 Nov;25(13):742. doi: 10.1016/j.purol.2015.08.054. French. No abstract available.

PMID:
26544250
32.

Critères de modification de la prise en charge chez une cohorte de patients atteints de cancer de la prostate et traités par analogue de la LHRH.

Lebret T, Rossi D, Zerbib M, Moreau J, Ruffion A, Neuzillet Y, Hennequin C.

Prog Urol. 2015 Nov;25(13):735. doi: 10.1016/j.purol.2015.08.038. French. No abstract available.

PMID:
26544234
33.

Intérêt de l'instillation postopératoire précoce de mitomycine C (IPOP) dans les tumeurs de vessie n'infiltrant pas le muscle : vers un âge limite ?

Abakka N, Shahrokh S, El Mrini M, Saighi D, Peyromaure M, Zerbib M, Xylinas E.

Prog Urol. 2014 Nov;24(13):848. doi: 10.1016/j.purol.2014.08.144. Epub 2014 Oct 30. French. No abstract available.

PMID:
26461670
34.

Impact pronostique de l'indice de masse corporelle sur le devenir oncologique des patients atteints d'une tumeur de la voie excrétrice traités par néphro-urétérectomie totale.

Mrini ME, Abakka N, Barry Delongchamps N, Saighi D, Peyromaure M, Zerbib M, Xylinas E.

Prog Urol. 2014 Nov;24(13):845. doi: 10.1016/j.purol.2014.08.138. Epub 2014 Oct 30. French. No abstract available.

PMID:
26461664
35.

Marges chirurgicales positives après cystectomie totale : une issue fatale ?

Such M, Delongchamps NB, Saighi D, Peyromaure M, Zerbib M, Xylinas E.

Prog Urol. 2014 Nov;24(13):807. doi: 10.1016/j.purol.2014.08.055. Epub 2014 Oct 30. French. No abstract available.

PMID:
26461581
36.

Impact pronostique du sexe féminin sur le devenir oncologique des patients atteints d'une tumeur de vessie infiltrant le muscle traités par cystectomie totale.

Dabi Y, Rouscoff Y, Mrini ME, Delonchamps NB, Saighi D, Peyromaure M, Zerbib M, Xylinas E.

Prog Urol. 2014 Nov;24(13):805. doi: 10.1016/j.purol.2014.08.051. Epub 2014 Oct 30. French. No abstract available.

PMID:
26461578
37.

Impact pronostique de l'indice de masse corporelle sur le devenir oncologique des patients atteints d'une tumeur de vessie infiltrant le muscle traités par cystectomie totale.

Rouscoff Y, Dabi Y, Mrini ME, Saighi D, Peyromaure M, Zerbib M, Xylinas E.

Prog Urol. 2014 Nov;24(13):805. doi: 10.1016/j.purol.2014.08.050. Epub 2014 Oct 30. French. No abstract available.

PMID:
26461576
38.

Cystectomie totale chez les octogénaires.

El Mrini M, Abakka N, Rouscoff Y, Barry Delongchamps N, Saighi D, Peyromaure M, Zerbib M, Xylinas E.

Prog Urol. 2014 Nov;24(13):804-5. doi: 10.1016/j.purol.2014.08.049. Epub 2014 Oct 30. French. No abstract available.

PMID:
26461574
39.

Validation en médecine générale d'un score visuel prostatique en images (SVPI), dans l'évaluation des symptômes du bas appareil urinaire (SBAU) associés à une hypertrophie bénigne de la prostate (HBP).

Descazeaud A, Coloby P, Davin JL, De la Taille A, Karsenty G, Kouri G, Rossi D, Jaquet D, Zerbib M.

Prog Urol. 2014 Nov;24(13):789. doi: 10.1016/j.purol.2014.08.016. Epub 2014 Oct 30. French. No abstract available.

PMID:
26461543
40.

Validation d'une échelle visuelle analogique (EVA) en médecine générale, dans l'évaluation des symptômes du bas appareil urinaire (SBAU) associés à une hypertrophie bénigne de la prostate (HBP).

Coloby P, Davin JL, De la Taille A, Descazeaud A, Karsenty G, Kouri G, Rossi D, Jaquet D, Zerbib M.

Prog Urol. 2014 Nov;24(13):789-90. doi: 10.1016/j.purol.2014.08.017. Epub 2014 Oct 30. French. No abstract available.

PMID:
26461542
41.

Gleason Score Determination with Transrectal Ultrasound-Magnetic Resonance Imaging Fusion Guided Prostate Biopsies--Are We Gaining in Accuracy?

Lanz C, Cornud F, Beuvon F, Lefèvre A, Legmann P, Zerbib M, Delongchamps NB.

J Urol. 2016 Jan;195(1):88-93. doi: 10.1016/j.juro.2015.07.021. Epub 2015 Jul 10.

PMID:
26165586
42.

Transient acquisition of pluripotency during somatic cell transdifferentiation with iPSC reprogramming factors.

Maza I, Caspi I, Zviran A, Chomsky E, Rais Y, Viukov S, Geula S, Buenrostro JD, Weinberger L, Krupalnik V, Hanna S, Zerbib M, Dutton JR, Greenleaf WJ, Massarwa R, Novershtern N, Hanna JH.

Nat Biotechnol. 2015 Jul;33(7):769-74. doi: 10.1038/nbt.3270. Epub 2015 Jun 22.

43.

Corrigendum: Derivation of novel human ground state naive pluripotent stem cells.

Gafni O, Weinberger L, Mansour AA, Manor YS, Chomsky E, Ben-Yosef D, Kalma Y, Viukov S, Maza I, Zviran A, Rais Y, Shipony Z, Mukamel Z, Krupalnik V, Zerbib M, Geula S, Caspi I, Schneir D, Shwartz T, Gilad S, Amann-Zalcenstein D, Benjamin S, Amit I, Tanay A, Massarwa R, Novershtern N, Hanna JH.

Nature. 2015 Apr 30;520(7549):710. doi: 10.1038/nature14370. Epub 2015 Apr 1. No abstract available.

PMID:
25830888
44.

Corrigendum: Deterministic direct reprogramming of somatic cells to pluripotency.

Rais Y, Zviran A, Geula S, Gafni O, Chomsky E, Viukov S, Mansour AA, Caspi I, Krupalnik V, Zerbib M, Maza I, Mor N, Baran D, Weinberger L, Jaitin DA, Lara-Astiaso D, Blecher-Gonen R, Shipony Z, Mukamel Z, Hagai T, Gilad S, Amann-Zalcenstein D, Tanay A, Amit I, Novershtern N, Hanna JH.

Nature. 2015 Apr 30;520(7549):710. doi: 10.1038/nature14369. Epub 2015 Apr 1. No abstract available.

PMID:
25830885
45.

Stem cells. m6A mRNA methylation facilitates resolution of naïve pluripotency toward differentiation.

Geula S, Moshitch-Moshkovitz S, Dominissini D, Mansour AA, Kol N, Salmon-Divon M, Hershkovitz V, Peer E, Mor N, Manor YS, Ben-Haim MS, Eyal E, Yunger S, Pinto Y, Jaitin DA, Viukov S, Rais Y, Krupalnik V, Chomsky E, Zerbib M, Maza I, Rechavi Y, Massarwa R, Hanna S, Amit I, Levanon EY, Amariglio N, Stern-Ginossar N, Novershtern N, Rechavi G, Hanna JH.

Science. 2015 Feb 27;347(6225):1002-6. doi: 10.1126/science.1261417. Epub 2015 Jan 1.

46.

Selection criteria for initiation and renewal of luteinizing hormone-releasing hormone agonist therapy in patients with prostate cancer: a French prospective observational study.

Lebret T, Davin JL, Hennequin C, Latorzeff I, Mignard JP, Moreau JL, Rossi D, Ruffion A, Zerbib M, Culine S.

Ther Adv Urol. 2014 Dec;6(6):205-14. doi: 10.1177/1756287214542418.

47.

Oncological outcomes of advanced muscle-invasive bladder cancer with a micropapillary variant after radical cystectomy and adjuvant platinum-based chemotherapy.

Masson-Lecomte A, Xylinas E, Bouquot M, Sibony M, Allory Y, Comperat E, Zerbib M, de la Taille A, Rouprêt M.

World J Urol. 2015 Aug;33(8):1087-93. doi: 10.1007/s00345-014-1387-1. Epub 2014 Sep 2.

PMID:
25179011
48.

TMPRSS2-ERG fusion transcripts expression in patients referred for prostate biopsy: combining detection in urine and needle rinse material.

Delongchamps NB, Younes P, Denjean L, Zerbib M, Bories PN.

World J Urol. 2015 Jun;33(6):807-11. doi: 10.1007/s00345-014-1359-5. Epub 2014 Jul 5.

PMID:
24997128
49.

[Pronostic value of parenchyma renal invasion of pT3 upper tract urinary carcinoma].

Bruzzi M, Le Goux C, Pignot G, Amsellem-Ouazana D, Vieillefond A, Patard JJ, Zerbib M.

Prog Urol. 2014 Jul;24(9):556-62. doi: 10.1016/j.purol.2013.12.005. Epub 2014 Jan 21. French.

PMID:
24975790
50.

Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib.

Beuselinck B, Lambrechts D, Van Brussel T, Wolter P, Cardinaels N, Joniau S, Lerut E, Karadimou A, Couchy G, Sebe P, Ravaud A, Zerbib M, Caty A, Paridaens R, Schöffski P, Verkarre V, Berger J, Patard JJ, Zucman-Rossi J, Oudard S.

Acta Oncol. 2014 Oct;53(10):1413-22. doi: 10.3109/0284186X.2014.918276. Epub 2014 May 30.

PMID:
24874929

Supplemental Content

Loading ...
Support Center